Cisen Pharmaceutical Co., Ltd.
SSE:603367.SS
14.89 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,981.572 | 4,462.349 | 4,066.088 | 3,782.593 | 3,674.158 | 4,112.786 | 3,808.078 | 2,962.517 | 2,564.801 | 2,496.972 | 2,388.355 | 2,205.982 | 2,051.722 | 1,531.421 |
| Cost of Revenue
| 1,729.094 | 1,912.699 | 1,789.293 | 1,684.647 | 1,570.901 | 1,750.682 | 1,621.743 | 1,449.23 | 1,499.302 | 1,575.915 | 1,522.24 | 1,400.514 | 1,214.037 | 920.7 |
| Gross Profit
| 2,252.478 | 2,549.65 | 2,276.796 | 2,097.946 | 2,103.257 | 2,362.103 | 2,186.336 | 1,513.286 | 1,065.5 | 921.057 | 866.115 | 805.468 | 837.685 | 610.721 |
| Gross Profit Ratio
| 0.566 | 0.571 | 0.56 | 0.555 | 0.572 | 0.574 | 0.574 | 0.511 | 0.415 | 0.369 | 0.363 | 0.365 | 0.408 | 0.399 |
| Reseach & Development Expenses
| 342.641 | 377.958 | 335.169 | 334.346 | 309.585 | 310.56 | 325.981 | 142 | 108.692 | 103.823 | 135.032 | 123.982 | 97.523 | 0 |
| General & Administrative Expenses
| 100.094 | 98.083 | 85.163 | 69.778 | 54.393 | 64.362 | 55.762 | 50.948 | 41.041 | 39.018 | 31.422 | 223.573 | 166.723 | 121.781 |
| Selling & Marketing Expenses
| 1,041.538 | 1,334.66 | 1,305.968 | 1,246.879 | 1,183.98 | 1,303.354 | 1,089.442 | 760.81 | 469.873 | 342.04 | 331.302 | 328.026 | 307.373 | 197.955 |
| SG&A
| 1,141.632 | 1,544.42 | 1,391.131 | 1,316.658 | 1,238.373 | 1,367.715 | 1,145.204 | 811.758 | 510.915 | 381.058 | 362.724 | 551.598 | 474.095 | 319.737 |
| Other Expenses
| 196.158 | 264.183 | 192.628 | 160.529 | 133.053 | 146.379 | 2.368 | 6.358 | 19.809 | 19.425 | 17.175 | 31.928 | 8.965 | 7.37 |
| Operating Expenses
| 1,680.43 | 2,030.746 | 1,918.927 | 1,811.533 | 1,681.011 | 1,824.654 | 1,614.722 | 1,074.344 | 756.919 | 607.14 | 588.264 | 569.121 | 488.161 | 331.183 |
| Operating Income
| 572.048 | 592.578 | 364.583 | 334.421 | 484.673 | 582.714 | 565.611 | 416.206 | 269.611 | 269.997 | 241.579 | 208.063 | 326.481 | 270.189 |
| Operating Income Ratio
| 0.144 | 0.133 | 0.09 | 0.088 | 0.132 | 0.142 | 0.149 | 0.14 | 0.105 | 0.108 | 0.101 | 0.094 | 0.159 | 0.176 |
| Total Other Income Expenses Net
| 3.726 | 3.279 | 1.609 | 1.711 | -0.157 | -0.604 | 2.368 | 6.358 | 18.929 | 15.417 | 24.32 | 31.159 | 5.733 | 7.494 |
| Income Before Tax
| 575.773 | 595.857 | 366.191 | 336.132 | 484.516 | 582.111 | 567.978 | 422.565 | 289.2 | 285.414 | 256.39 | 239.222 | 335.372 | 277.682 |
| Income Before Tax Ratio
| 0.145 | 0.134 | 0.09 | 0.089 | 0.132 | 0.142 | 0.149 | 0.143 | 0.113 | 0.114 | 0.107 | 0.108 | 0.163 | 0.181 |
| Income Tax Expense
| 60.833 | 70.43 | 13.806 | 2.23 | 47.156 | 67.317 | 64.924 | 56.887 | 44.57 | 39.791 | 37.448 | 32.188 | 51.514 | 40.755 |
| Net Income
| 508.906 | 521.338 | 349.959 | 334.146 | 438.784 | 514.58 | 503.545 | 367.222 | 246.882 | 246.855 | 220.152 | 208.299 | 283.857 | 236.93 |
| Net Income Ratio
| 0.128 | 0.117 | 0.086 | 0.088 | 0.119 | 0.125 | 0.132 | 0.124 | 0.096 | 0.099 | 0.092 | 0.094 | 0.138 | 0.155 |
| EPS
| 1.12 | 1.15 | 0.78 | 0.74 | 0.97 | 1.14 | 1.11 | 0.97 | 0.7 | 0.7 | 0.62 | 0.65 | 0.88 | 0.74 |
| EPS Diluted
| 1.12 | 1.15 | 0.78 | 0.74 | 0.97 | 1.14 | 1.11 | 0.97 | 0.7 | 0.7 | 0.62 | 0.65 | 0.88 | 0.74 |
| EBITDA
| 805.57 | 840.031 | 604.299 | 562.563 | 655.577 | 746.859 | 745.565 | 618.338 | 365.369 | 469.301 | 430.548 | 236.347 | 349.523 | 288.577 |
| EBITDA Ratio
| 0.202 | 0.188 | 0.149 | 0.149 | 0.178 | 0.182 | 0.196 | 0.209 | 0.142 | 0.188 | 0.18 | 0.107 | 0.17 | 0.188 |